LYLianbao Ye

Lianbao Ye

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article

Previous Organizations / Institutes

The organizations / institutes from the scholar's other articles in the past ten years


Lianbao Ye has a total of 115 co-authors. Here are the top co-authors by number of shared publications:

  • Ming Li

    School of Basic Medical Sciences, Guangdong Pharmaceutical University, Guangzhou, 510006, China

    7 shared publications
  • Gong Chen

    School of Pharmacy, Guangdong Pharmaceutical University, Guangzhou 510006, China

    6 shared publications
  • Weiqiang Chen

    School of Basic Medical Sciences, Guangdong Pharmaceutical University, Guangzhou, China

    6 shared publications
  • Xiaobao Jin

    Guangdong Key Laboratory of Pharmaceutical Bioactive Substances Guangdong Pharmaceutical University Guangzhou 510006 People's Republic of China

    6 shared publications
  • Yan Luo

    School of Pharmacy Guangdong Pharmaceutical University Guangzhou 510006 China

    5 shared publications
  • Qingfu Lai

    School of Pharmacy Guangdong Pharmaceutical University Guangzhou 510006 China

    4 shared publications

Latest Publications

  • Open Access

    Evaluation of In Vitro and In Vivo Anti-Tumor Effects and Pharmacokinetics of an Aniline–Pyrimidine Derivative B9

    by Gong Chen, Huisha Liang, Bingxin Lu, Siyuan Dai, Ming Li, Yan Li, Ying Liu, Lianbao Ye

    Non-small cell lung cancer (NSCLC) ranks among the malignancies with the highest global incidence and mortality rates. This study focused on a previous reported aniline–pyrimidine derivative, B9, which exhibited an IC50 of 21.43 μM against A549 cells. Herein, we further investigated its anti-NSCLC efficacy both in vitro and in vivo. The anti-proliferation assay proved B9 inhibits A549 cell proliferation in a concentration- and time-dependent manner, indicating B9 may have a good long-term effect in inhibiting the growth and division of cancer cells. The hemolysis assay revealed that B9 is non-hemolytic, with no observable hemolytic activity toward red blood cells, thereby confirming its preliminary biocompatibility. An in vivo efficacy study revealed that B9 effectively suppresses tumor growth within a low safe concentration of 2 μM in zebrafish models, confirming the anti-tumor efficacy of B9 was well preserved in animal models. Pharmacokinetic profiling showed B9 possesses unique metabolic profiles in rats and provides useful information of drug metabolism in vivo. Collectively, these findings establish B9 as a promising lead compound worthy of further development for NSCLC treatment.

  • Open Access

    Studies on the Lewis acid catalyzed synthesis of isoxazolidin-3-ones

    by Yining Xuan, Lianbao Ye, Lilan Jin, Weiqi Li

    The reaction of α, β-epoxy esters with N-alkyl-1-phenylmethanimine oxides in the presence of a Lewis acid was explored in this study. A substrate sustained-release strategy was successfully employed to overcome the inherent conflict between substrate activation and catalyst poisoning, allowing for the efficient synthesis of a variety of substituted isoxazolidin-3-ones. The reaction employs inexpensive and readily available starting materials, proceeds under mild conditions, and demonstrates broad substrate compatibility. Moreover, when chiral epoxy substrates were used, the products were obtained with high retention of enantiomeric purity.

  • Open Access

    Exploring the role of two polypeptide nanofiber gels derived from RADA16-I self-assembly in accelerating burn wound healing

    by Congjing Song, Sijia Li, Chenyang Zhang, Jiale Li, Ming Li, Lianbao Ye, Weiqiang Chen

    This study systematically evaluates the therapeutic effects and molecular mechanisms of peptide nanofiber gels RG and RJ in deep second-degree burn wound healing. The gels are composed of the self-assembling peptide RADA16-I (R) conjugated with either a GLP-1 analog (G) or Jagged-1 protein (J), both of which exhibit good physicochemical properties, including well-defined three-dimensional nanofiber architectures, transparent gel consistency, and significantly enhanced mechanical strengths (storage modulus increased by ~ 4.3-fold for RG and ~ 7.09-fold for RJ) with high composite viscosities (5.36 Pa·s for RG; 7.08 Pa·s for RJ). In vitro experiments demonstrated that RG and RJ significantly promoted cell proliferation and migration. In vivo studies revealed that RG and RJ accelerated the healing of deep second-degree burn wounds through significant angiogenesis, reduction of systemic inflammation, and enhanced tissue regeneration. Notably, after 14 days, the wound closure rates in the RG and RJ groups reached 89.5% and 76.8%, respectively, compared to 70.1% in the R group and 67% in the control group. This difference can be attributed to their advantages in reducing systemic inflammation, promoting vascular formation during the healing process, and increasing collagen deposition. Our findings suggest that RG and RJ nanofiber gels hold great potential as innovative solutions for the care of deep second-degree burn wounds.


  • Discovery of novel PDE4 degraders with in vivo anti-inflammatory efficacy

    by Yuanhui Liu, Hongliang Yao, Yanghui Ou, Lishan Hu, Wei Pan, Mengjie Li, Yali Zhang, Jun Wang, Jiaxin Chen, Xudong Qian, et al.


  • Design, Synthesis, and Anti‐Glioma Activity Evaluation of Dehydroabietic Acid Derivatives

    by Yuanhui Liu, Yifeng Qiu, Ming Li, Ying Liu, Yan Luo, Gong Chen, Lianbao Ye

    Dehydroabietic acid (DHAA) is a common natural product with a broad range of biological activities. In previous research, our group identified a range of dehydroabietic acid derivatives with strong anti‐glioma activity. In order to search for better anti‐glioma drugs candidates, new chalcone derivatives A1‐A10 and B1‐B10 were designed and synthesized in this study. The antiproliferative activity of these derivatives against U87 glioma cells was tested by CCK‐8 assay, in which A10 has the best IC 50 value of 11.39 µM. Scratch and cloning studies further confirmed that A10 strongly inhibited the proliferation and colony‐forming activity of U87 cells. The antiproliferative activity of A10 on U87 cells showed some concentration dependence manner and the pKa values of A10 were within the desirable range of anti‐gliomas drugs. In addition, molecular docking revealed hydrogen bonding interaction was formed between A10 and the target protein. These results suggest that A10 may be a promising DHAA‐derived lead compound that deserves further strategic optimization in search of the anticancer candidates against glioma.

  • Design, Synthesis, Anticancer Evaluation and In Silico Studies of Imidazole Pyrazine Compounds

    by Gong Chen, Weiwei Li, Yuanhui Liu, Tong Li, Wenrun Zhu, Ying Liu, Xiaobao Jin, Qinghua Mei, Lianbao Ye

    The present study focused on design and synthesis novel imidazolopyrazine derivatives, investigate the effect of them on the proliferation and migration of several human cancer cell lines by CCK‐8 method, and interactions with the JAKs by reverse molecular docking. It was found that most of the synthesized imidazolopyrazin derivatives exhibited excellent inhibitory effects towards three tested tutor cells in vitro. Among them, three compounds have IC50 values much lower than Fluorouracil while show low toxicity to normal cells L‐02. The migration ability assay have proved that A6 and A9 effectively inhibit the migration of tumor cells. Reverse molecular docking studies indicated that the potent targets of these derivatives are JAKs as they well docked into kinases with low energy. These finding suggest that imidazo[1,5‐a]pyrazin derivatives may be lead compounds for developing potent JAK targeted anticancer candidates.


  • Antimicrobial activity and mechanism of anti-MRSA of phloroglucinol derivatives

    by Xianjing Yang, Xinjiao Gao, Jiayi Ou, Gong Chen, Lianbao Ye

    Background In previous studies, authors have completed the total synthesis of several phloroglucinol natural products and synthesized a series of their derivatives, which were tested with good biological activities. Objectives To discover anti-MRSA lead compound and study their mechanism of action. Methods Phloroglucinol derivatives were tested to investigate their activities against several gram-positive strains including Methicillin-resistant Staphylococcus aureus (MRSA). The mechanism study was conducted by determining extracellular potassium ion concentration, intracellular NADPH oxidase content, SOD activity, ROS amount in MRSA and MRSA survival rate under A5 treatment. The in vitro cytotoxicity test of A5 was conducted. Results The activity of monocyclic compounds was stronger than that of bicyclic compounds, and compound A5 showed the best MIC value of 0.98 μg/mL and MBC value of 1.95 μg/mL, which were 4–8 times lower than that of vancomycin. The mechanism study of A5 showed that it achieved anti-MRSA effect through membrane damage, which is proved by increased concentration of extracellular potassium ion after A5 treatment. Another possible mechanism is the over ROS production induced cell death, which is suggested by observed alternation of several reactive oxygen species (ROS) related indicators including NADPH concentration, superoxide dismutase (SOD) activity, ROS content and bacterial survival rate after A5 treatment. The cytotoxicity results in vitro showed that A5 was basically non-toxic to cells. Conclusion Acylphloroglucinol derivative A5 showed good anti-MRSA activity, possibly via membrane damage and ROS-mediated oxidative stress mechanism. It deserves further exploration to be a potential lead for the development of new anti-MRSA agent. Graphical Abstract


  • Anti‐Herpes Simplex Virus Type 1 Activity Evaluation of Natural Derived Phloroglucinol Derivatives and Their Molecular Mechanisms Study

    by Haiyan Mai, Junjian Li, Yuyan Luo, Jiayi Ou, Gong Chen, Lianbao Ye

    HSV‐1 is a common infection that can cause cold sores. In this study, the anti‐HSV‐1 virus activity of three series compounds A1–A9, B1–B12, C1–C22 was screened by MTT assay, qRT‐PCR assay, Western blot assay and viruses’ plaque assays. The results of MTT assay disclosed that phloroglucinol derivatives C2 and C3 effectively inhibited the death of HSV‐1 infected vero cells with the CC50 values of C2 and C3 were 72.64 μmol/L and 32.62 μmol/L in HaCaT cells, 137.6 μmol/L and 48.55 μmol/L in Hela cells. The IC50 values of C3 in vero cells and Hela cells were 19.26 μmol/L and 22.98 μmol/L, respectively. In the qRT‐PCR experiments, it showed that C2 and C3 effectively reduced the synthesis of HSV‐1 early viral gene VP16 and late viral gene gD. The Western blot results showed that both C2 and C3 inhibited the expression of HSV‐1 gD protein in a concentration‐dependent manner. Lastly, viruses’ plaque assay results showed that C2 and C3 inhibited the production of HSV‐1 progeny virus in Hela cells and HaCaT cells in a concentration‐dependent manner. Taken together, these results suggest that C2 and C3 are promising candidate that warrants further attention in the development of anti‐HSV‐1 drugs.


  • Design, Synthesis, and Bioactivity Evaluation of Novel Rosin Diterpenoid Derivatives as Potential Anti‐glioma Agents

    by Jiayi Ou, Weiyun Tan, Gong Chen, Xianjing Yang, Yan Luo, Xiaobao Jin, Lianbao Ye

    Glioma is the most common brain tumor and its treatment options are limited. Abietic acid and dehydroabietic acid are tricyclic diterpenoid oxygen compounds with strong lip solubility and anti‐glioma activity. In this study, novel rosin diterpenoid derivatives were designed and synthesized using abietic acid and dehydrogenated abietic acid as lead compounds and their activities against T98G, U87MG, and U251 cells were evaluated by CCK‐8 methods. The in vivo activity of compounds with stronger activity in vitro was preliminarily studied through the Zebrafish model. The results showed that the IC50 values of B6, B8, B10, and B12 were 11.47 to 210.6 μM, which were exhibited higher antiproliferative potency against T98G, U87MG, and U251. The scratch experiment showed that B12 inhibited the migration of T98G in a time‐dependent and concentration‐dependent manner. The results of in vivo activity further explained that B12 could inhibit the proliferation of the T98G. The pKa values of B6, B8, B10, and B12 were 7.17 to 7.35, which were within the ideal range of glioma drugs. The ADME predictions indicated that these derivatives could pass through the blood‐brain barrier. In addition, molecular docking primarily explained interaction between compounds and protein. These results suggested that B12 should be a promising candidate that merits further attention in the development of anti‐glioma drugs.